drugset / Trial / NCT04472858
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
Phase 1
Unknown
30 enrolled
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CStone Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and treatment effect of CS1001 in combination with Donafenib in patients with advanced solid tumors.
Timeline
- Start
- 2020-10-15
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 100 mg | Oral |
| Subject | Donafenib | Small molecule | 200 mg | Oral |
| Subject | Sugemalimab | Monoclonal antibody | — | Intravenous |